Imatinib NORMON 400 mg Filmtabletten Germania - germană - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

imatinib normon 400 mg filmtabletten

laboratorios normon, s.a. (8121281) - imatinibmesilat - filmtablette - teil 1 - filmtablette; imatinibmesilat (30739) 478 milligramm

Imatinib NORMON 100 mg Filmtabletten Germania - germană - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

imatinib normon 100 mg filmtabletten

laboratorios normon, s.a. (8121281) - imatinibmesilat - filmtablette - teil 1 - filmtablette; imatinibmesilat (30739) 119,5 milligramm

Imatinib Glenmark 400 mg Filmtabletten Germania - germană - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

imatinib glenmark 400 mg filmtabletten

glenmark arzneimittel gmbh (8139306) - imatinibmesilat - filmtablette - teil 1 - filmtablette; imatinibmesilat (30739) 478 milligramm

Imatinib Glenmark 100 mg Filmtabletten Germania - germană - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

imatinib glenmark 100 mg filmtabletten

glenmark arzneimittel gmbh (8139306) - imatinibmesilat - filmtablette - teil 1 - filmtablette; imatinibmesilat (30739) 119,5 milligramm

Imatinib Ribosepharm 400 mg Filmtabletten Germania - germană - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

imatinib ribosepharm 400 mg filmtabletten

hikma pharma gmbh (3220831) - imatinibmesilat - filmtablette - teil 1 - filmtablette; imatinibmesilat (30739) 477,88 milligramm

Imatinib Ribosepharm 100 mg Filmtabletten Germania - germană - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

imatinib ribosepharm 100 mg filmtabletten

hikma pharma gmbh (3220831) - imatinibmesilat - filmtablette - teil 1 - filmtablette; imatinibmesilat (30739) 119,47 milligramm

Imatinib Pensa 100 mg Filmtabletten Germania - germană - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

imatinib pensa 100 mg filmtabletten

pensa pharma gmbh (8135998) - imatinibmesilat - filmtablette - teil 1 - filmtablette; imatinibmesilat (30739) 119,5 milligramm

Imatinib Accord Uniunea Europeană - germană - EMA (European Medicines Agency)

imatinib accord

accord healthcare s.l.u. - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. außer bei patienten mit neu diagnostiziertem chronischen phase der cml gibt es keine kontrollierten studien zeigen einen klinischen nutzen oder erhöhte überlebenschancen für diese krankheiten. .

Imatinib HEXAL 100 mg Filmtabletten Germania - germană - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

imatinib hexal 100 mg filmtabletten

h e x a l aktiengesellschaft (3079284) - imatinibmesilat - filmtablette - teil 1 - filmtablette; imatinibmesilat (30739) 119,5 milligramm

Imatinib HEXAL 400 mg Filmtabletten Germania - germană - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

imatinib hexal 400 mg filmtabletten

h e x a l aktiengesellschaft (3079284) - imatinibmesilat - filmtablette - teil 1 - filmtablette; imatinibmesilat (30739) 478 milligramm